Abstract
The parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal complication seen in Parkinson’s disease (PD) patients, most commonly following reduction or cessation of antiparkinson medications. Clinically it resembles neuroleptic malignant syndrome with rigidity, pyrexia, and reduced conscious level. There may be features of autonomic instability, and serum creatine kinase (CK) may be elevated. Complications of PHS include acute renal failure, aspiration pneumonia, deep venous thrombosis/pulmonary embolism, and disseminated intravascular coagulation (DIC). Management consists of dopaminergic drug replacement, supportive measures, and treatment of complications. The prognosis is improved with early recognition and management. Mortality of up to 4% has been reported, but an additional one-third of patients have permanent sequelae. Patients and physicians should be warned against sudden reduction in antiparkinson medications. PHS should always be considered in a patient with parkinsonism who presents with an acute deterioration in symptoms.
Similar content being viewed by others
References
Delay J, Pichot P, Lemperiere T, et al. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris). 1960;118(1):145–52.
Caroff SN, Mann SC, Campbell EC, et al. Neuroleptic malignant syndrome. In: Frucht SJ, Fahn S, editors. Movement disorder emergencies diagnosis and treatment. New York: Humana Press; 2005. p. 41–52.
Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res. 1995;29:233–44. doi:10.1016/0022-3956(95)00007-R.
Kipps CM, Fung VS, Grattan-Smith P, et al. Movement disorder emergencies. Mov Disord. 2005;20:322–34. doi:10.1002/mds.20325.
Berardi D, Amore M, Keck PE Jr, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998;44:748–54. doi:10.1016/S0006-3223(97)00530-1.
Keck PE Jr, Pope HG Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 1989;46:914–8.
Toru M, Matsuda O, Makiguchi K, et al. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis. 1981;169:324–7. doi:10.1097/00005053-198105000-00011.
Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson’s disease and related disorders. Parkinsonism Relat Disord. 2003;9(Suppl 1):S31–41. doi:10.1016/S1353-8020(02)00122-0.
Konagaya M, Goto Y, Matsuoka Y, et al. Neuroleptic malignant syndrome-like condition in multiple system atrophy. J Neurol Neurosurg Psychiatry. 1997;63:120–1.
Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–13.
Mayeux R, Stern Y, Mulvey K, et al. Reappraisal of temporary levodopa withdrawal (“drug holiday”) in Parkinson’s disease. N Engl J Med. 1985;313:724–8.
Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multi-centre European study. Mov Disord. 2008; in press.
Douglas A, Morris J. It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson’s disease. Age Ageing. 2006;35:640–1. doi:10.1093/ageing/afl096.
Gaig C, Marti MJ, Tolosa E, et al. Parkinsonism-hyperpyrexia syndrome not related to antiparkinsonian treatment withdrawal during the 2003 summer heat wave. J Neurol. 2005;252:1116–9. doi:10.1007/s00415-005-0798-8.
Grace JB, Thompson P. Neuroleptic malignant like syndrome in two patients on cholinesterase inhibitors. Int J Geriatr Psychiatry. 2006;21:193–4. doi:10.1002/gps.1441.
Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson’s disease. Mov Disord. 2001;16:960–2. doi:10.1002/mds.1166.
Mizuta E, Yamasaki S, Nakatake M, et al. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period. Neurology. 1993;43:1048–9.
Shimada J, Sakakibara R, Uchiyama T, et al. Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a chronically constipated parkinsonian patient. Eur J Neurol. 2006;13:306–7. doi:10.1111/j.1468-1331.2006.01151.x.
Factor SA. Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson’s disease patient while actively treated with deep brain stimulation. Mov Disord. 2007;22:148–9. doi:10.1002/mds.21172.
Factor SA, Santiago A. Parkinsonism-hyperpyrexia syndrome in Parkinson’s disease. In: Movement disorder emergencies: Diagnosis and treatment . New York: Humana Press; 2005. p. 29–41.
Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease. Neurology. 1999;52:777–81.
Ueda M, Hamamoto M, Nagayama H, et al. Biochemical alterations during medication withdrawal in Parkinson’s disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry. 2001;71:111–3. doi:10.1136/jnnp.71.1.111.
Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50:18–25.
Serrano-Duenas M. Neuroleptic malignant syndrome-like, or—dopaminergic malignant syndrome—due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord. 2003;9:175–8. doi:10.1016/S1353-8020(02)00035-4.
Hashimoto T, Tokuda T, Hanyu N, et al. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2003;9 Suppl 1:S25–30. doi:10.1016/S1353-8020(02)00119-0.
Ikebe S, Harada T, Hashimoto T, et al. Prevention and treatment of malignant syndrome in Parkinson’s disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord. 2003;9 Suppl 1:S47–9. doi:10.1016/S1353-8020(02)00123-2.
Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21. doi:10.1186/1750-1172-2-21.
Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant syndrome. Successful treatment with bromocriptine. J Am Med Assoc. 1983;249:386–8. doi:10.1001/jama.249.3.386.
Sato Y, Asoh T, Metoki N, et al. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74:574–6. doi:10.1136/jnnp.74.5.574.
Magdalinou KN, Martin A, Kessel B. Prescribing medications in Parkinson’s disease (PD) patients during acute admissions to a District General Hospital. Parkinsonism Relat Disord. 2007;13:539–40. doi:10.1016/j.parkreldis.2006.11.006.
Grosset K, Needleman F, MacPhee G, et al. Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: a clinical series and five-drug dose conversion table. Mov Disord. 2004;19:1370–4. doi:10.1002/mds.20210.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Newman, E.J., Grosset, D.G. & Kennedy, P.G.E. The Parkinsonism-Hyperpyrexia Syndrome. Neurocrit Care 10, 136–140 (2009). https://doi.org/10.1007/s12028-008-9125-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-008-9125-4